Vindesine and high-dose cisplatin in the treatment of advanced non-small-cell lung cancer
- 1 January 1985
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 13 (2), 73-77
- https://doi.org/10.1002/mpo.2950130206
Abstract
Seventeen patients with advanced non-small-cell lung cancer (NSCLC) were entered on a combination chemotherapy protocol including vindesine and high-dose cisplatin. All patients had measurable disease and had not previously received chemotherapy. All patients entered were evaluable for toxicity and response. Tumor regression was limited to one complete and one partial response (response rate, 11.7%; 95% confidence limits, 0 to 27%). The complete and partial response lasted 260 + and 82 days, respectively. For the 15 nonresponding patients, the median time to disease progression was 76 days. Median survival was 141 days for the whole group. Significant toxic effects were vindesine-related peripheral neuropathy and cisplatin-in-duced emesis. Myelosuppression was mild and manageable. The response for the vindesine-cisplatin combination observed in our study is inferior to that seen in a previous vindesine-cisplatin trial reported by others. Thus, the true value of this two-drug regimen in the treatment of NSCLC remains to be established.Keywords
This publication has 6 references indexed in Scilit:
- Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinomaCancer, 1982
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage SchedulesAnnals of Internal Medicine, 1981
- Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary resultsCancer Treatment Reviews, 1980
- CIS-DICHLORODIAMMINEPLATINUM(II) ALONE FOLLOWED BY ADRIAMYCIN PLUS CYCLOPHOSPHAMIDE AT PROGRESSION VERSUS CIS-DICHLORODIAMMINEPLATINUM(II), ADRIAMYCIN, AND CYCLOPHOSPHAMIDE IN COMBINATION FOR ADENOCARCINOMA OF LUNG1978